Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Moore

Showing results (1251-1260 of 1,421) with videos related to

Pageof 143
Sort By:
Nature|October 22, 2025
Designing allosteric modulators to change GPCR G protein subtype selectivityMadelyn N Moore, Kelsey L Person, Valeria L Robleto, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms resultsRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Gynecologic Oncology|October 19, 2019
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG studyShannon N Westin, Michael W Sill, Robert L Coleman, et al.
Gynecologic Oncology|February 27, 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancerRebecca C Arend, Bradley J Monk, Thomas J Herzog, et al.
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Journal of Medical Virology|July 5, 2025
Kaposi Sarcoma-Associated Herpesvirus Sequencing in People Living With HIV in the Southern United States Reveals Subtype Diversity and Multiple InfectionsVickie A Marshall, Sheena M Knights, Elena M Cornejo Castro, et al.
Oncogene|March 1, 2026
Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasisAbbey E Williams, Erica J Hoffmann, David R Inman, et al.
JCI Insight|May 4, 2018
First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitisIan A Myles, Noah J Earland, Erik D Anderson, et al.
The Journal of Bone and Joint Surgery. American Volume|February 25, 2025
Admission Neutrophil-to-Lymphocyte Ratio Is Superior to WBC Count at Predicting the Presence and Severity of Pediatric Musculoskeletal InfectionBrian Q Hou, Anoop S Chandrashekar, Naadir H Jamal, et al.
JACC. Cardiooncology|January 13, 2025
Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and <i>JACC: CardioOncology</i> Expert Panel RecommendationsDarryl P Leong, Sarah Waliany, Husam Abdel-Qadir, et al.
Pageof 143

Showing results (1251-1260 of 1,421) with videos related to

Sort By:
Pageof 143
Nature|October 22, 2025
Designing allosteric modulators to change GPCR G protein subtype selectivityMadelyn N Moore, Kelsey L Person, Valeria L Robleto, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms resultsRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Gynecologic Oncology|October 19, 2019
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG studyShannon N Westin, Michael W Sill, Robert L Coleman, et al.
Gynecologic Oncology|February 27, 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancerRebecca C Arend, Bradley J Monk, Thomas J Herzog, et al.
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Journal of Medical Virology|July 5, 2025
Kaposi Sarcoma-Associated Herpesvirus Sequencing in People Living With HIV in the Southern United States Reveals Subtype Diversity and Multiple InfectionsVickie A Marshall, Sheena M Knights, Elena M Cornejo Castro, et al.
Oncogene|March 1, 2026
Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasisAbbey E Williams, Erica J Hoffmann, David R Inman, et al.
JCI Insight|May 4, 2018
First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitisIan A Myles, Noah J Earland, Erik D Anderson, et al.
The Journal of Bone and Joint Surgery. American Volume|February 25, 2025
Admission Neutrophil-to-Lymphocyte Ratio Is Superior to WBC Count at Predicting the Presence and Severity of Pediatric Musculoskeletal InfectionBrian Q Hou, Anoop S Chandrashekar, Naadir H Jamal, et al.
JACC. Cardiooncology|January 13, 2025
Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and <i>JACC: CardioOncology</i> Expert Panel RecommendationsDarryl P Leong, Sarah Waliany, Husam Abdel-Qadir, et al.
Pageof 143